is a R&D driving pharmaceutical company focus on niche specialty generics and intermediates, with high tech barrier, such as multi-chiral and fermentation
Our manufacturing sites have been approved by FDA EDQM PMDA KFDA and CFDA.
We have full pipeline in ADC cytotoxic payloads, its starting material, and linkers:
- Maytansinoids: Ansamitocin P3, DM1 DM4 DM1-SMCC
- Auristatins: MMAE MMAF and intermediates, Vc-MMAE